Cytotoxicity of peroxisome proliferator-activated receptor α and γ agonists in renal proximal tubular cell lines

被引:11
作者
Giral, Hector [1 ]
Villa-Bellosta, Ricardo [1 ]
Catalan, Julia [1 ]
Sorribas, Victor [1 ]
机构
[1] Univ Zaragoza, Lab Mol Toxicol, E-50013 Zaragoza, Spain
关键词
PPAR; peroxisome proliferator; WY14643; clofibrate; ciglitazone; pioglitazone; proximal tubule; cytotoxicity; OK cells; LLC-PK1; MCT; kidney;
D O I
10.1016/j.tiv.2007.03.021
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Fibrates and thiazolidinediones are agonists of peroxisome proliferator-activated receptors (PPAR) a and gamma, pharmacologically designed to control dyslipidemia and insulin resistance, respectively. Several works have reported the toxicity of some agonists in a number of tissues. In this work we have analyzed the toxicity of two PPAR alpha (WY14643 and clofibrate) and two PPAR gamma (pioglitazone and ciglitazone) agonists, using three different renal proximal tubular cell lines: Opossum OK, pig LLC-PK1, and murine MCT. Cell death was determined by the activity of intracellular lactate dehydrogenase. WY14643 and ciglitazone increased cell death with LC50 values of 92-1241 mu M and 8.6-14.8 mu M, respectively, depending on the cell line. Clofibrate and pioglitazone were, however, non-cytotoxic even at concentrations of 10 and 100 higher than the corresponding EC50, which suggests that cell death is independent of PPAR activation. Discrimination between apoptosis or necrosis was analyzed by light microscopy and stress fiber morphology, double staining with acridine orange and ethidium bromide, binding of annexin V, caspase-3 activity, and DNA laddering. With these methods, no signs of apoptosis were observed, which suggests a direct necrosis of the compounds on these renal proximal tubular cell lines. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1066 / 1076
页数:11
相关论文
共 42 条
[31]   Thyroid hormone stimulation of Na/P-i-cotransport in opossum kidney cells [J].
Sorribas, V ;
Markovich, D ;
Verri, T ;
Biber, J ;
Murer, H .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1995, 431 (02) :266-271
[32]   Therapeutic roles of peroxisome proliferator-activated receptor agonists [J].
Staels, B ;
Fruchart, JC .
DIABETES, 2005, 54 (08) :2460-2470
[33]   Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators [J].
Theocharis, S ;
Margeli, A ;
Vielh, P ;
Kouraklis, G .
CANCER TREATMENT REVIEWS, 2004, 30 (06) :545-554
[34]   Troglitazone inhibits isolated cell proliferation, and induces apoptosis in isolated rat mesangial cells [J].
Tsuchiya, T ;
Shimizu, H ;
Shimomura, K ;
Mori, M .
AMERICAN JOURNAL OF NEPHROLOGY, 2003, 23 (04) :222-228
[35]   Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats [J].
Weissgarten, J ;
Berman, S ;
Efrati, S ;
Rapoport, M ;
Averbukh, Z ;
Feldman, L .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (05) :1198-1204
[36]   Troglitazone acts by PPARγ and PPARγ-independent pathways on LLC-PK1-F+ acid-base metabolism [J].
Welbourne, T ;
Friday, E ;
Fowler, R ;
Turturro, F ;
Nissim, I .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2004, 286 (01) :F100-F110
[37]   The PPARs: From orphan receptors to drug discovery [J].
Willson, TM ;
Brown, PJ ;
Sternbach, DD ;
Henke, BR .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (04) :527-550
[38]   The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones [J].
Willson, TM ;
Cobb, JE ;
Cowan, DJ ;
Wiethe, RW ;
Correa, ID ;
Prakash, SR ;
Beck, KD ;
Moore, LB ;
Kliewer, SA ;
Lehmann, JM .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) :665-668
[39]   GLUCOCORTICOID-INDUCED THYMOCYTE APOPTOSIS IS ASSOCIATED WITH ENDOGENOUS ENDONUCLEASE ACTIVATION [J].
WYLLIE, AH .
NATURE, 1980, 284 (5756) :555-556
[40]   Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts [J].
Zafiriou, S ;
Stanners, SR ;
Saad, S ;
Polhill, TS ;
Poronnik, P ;
Pollock, CA .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (03) :638-645